Haugnes HS et al. (2007) Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 18: 241–248
Although advances in the treatment of testicular cancer have markedly increased life expectancy, a number of reports have indicated an increased risk of cardiovascular disease in survivors, possibly mediated through the metabolic syndrome. Haugnes et al. examined the prevalence of metabolic syndrome in a national follow-up study involving 1,135 survivors of testicular cancer. Median follow-up was 11.1 years.
Participants were classified into the following groups on the basis of treatment regimen: surgery (n = 225); radiotherapy (n = 446); chemotherapy with a cumulative cisplatin dose of ≤850 mg (n = 376); and chemotherapy with a cumulative cisplatin dose of >850 mg (n = 88). A control cohort of 1,150 men was recruited from the Norwegian population-based Tromsø Study. Metabolic syndrome was defined, in accordance with a modified US National Cholesterol Education Program definition, as the presence of two or more of the following components: obesity; hypertension; hypercholesterolemia; or diabetes.
Metabolic syndrome was documented in 40% of the patient population. The age-adjusted prevalence of metabolic syndrome was markedly higher in the two chemotherapy groups than in the surgery group (odds ratios: 1.48 for cisplatin ≤850 mg and 2.76 for cisplatin >850 mg). Compared with the control cohort, the age-adjusted prevalence of metabolic syndrome was not increased in the total patient population. By contrast, subgroup analysis revealed an odds ratio of 2.1 for metabolic syndrome in the cisplatin >850 mg group compared with the control cohort. On the basis of these results, the authors suggest that clinicians should consider screening cisplatin-treated survivors of testicular cancer for metabolic syndrome.
Change history
17 May 2018
This article was published with the same DOI as a previous publication. A new DOI has been assigned and registered at Crossref, and has been corrected in the article.
Rights and permissions
About this article
Cite this article
High cisplatin dose increases risk of metabolic syndrome in survivors of testicular cancer. Nat Rev Urol 4, 299 (2007). https://doi.org/10.1038/ncponc0800x
Issue Date:
DOI: https://doi.org/10.1038/ncponc0800x